What is it about?
SPARC is a matrix glycoprotein that plays a role in progression and invasiveness of neoplasms. In this study, we examined the potential role of SPARC in invasive pituitary adenomas. Forty pituitary adenomas have been examined with histopathological and immunohistochemical techniques. The cohort has been classified into two groups as invasive (n = 25) and non-invasive (n = 15) utilizing the Hardy classification.
Featured Image
Why is it important?
We proposed SPARC might have an important role in predicting clinic behavior and distinguishing invasive and noninvasive pituitary adenomas. SPARC antibody can be supplemented in pituitary immunohistochemistry panel as a predictive biomarker for invasive adenomas. Unfortunately, lack of significant SPARC expression in tumor progression, sellar dilatation, erosion, and destruction suggest that SPARC scores are not correlated with invasion and progression in pituitary adenomas.
Perspectives
SPARC, as a matrix glycoprotein, has no role in progression and invasiveness of pituitary adenomas. Therefore other omics prognostic and predictive biomarkers should be investigated to predict biologic behavior of pituitary adenomas to tailor appropriate treatment modalities.
Prof.Dr. AYDIN SAV
Acibadem Universitesi
Read the Original
This page is a summary of: Correlation between SPARC (Osteonectin) expression with immunophenotypical and invasion characteristics of pituitary adenomas, Apmis, December 2014, Wiley,
DOI: 10.1111/apm.12342.
You can read the full text:
Contributors
The following have contributed to this page
